For over 20 years, the team at the University of Washington Medical Center has been working to treat liver cancer by addressing its most common underlying cause: Hepatitis C. Hepatitis is one of the leading causes of the development of liver cancer, but it is also one of the most common complications occurring in patients post-transplant. While drugs are currently available to treat Hepatitis C, they are often harmful for patients and can carry some serious side effects. University of Washington Medical Center has been actively involved in clinical trials and studies of new drugs that are emerging for the treatment of Hepatitis C that could increase success rates and reduce risk factors involved with treatment.
www.uwmedicine.org